Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | IDUA | P35475 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | GGH | Q92820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13448062 | 1.00 | FOLH1 (0.39) | FOLH1NOS2NOS1NOS3CYP1A2 | |
| SCHEMBL27041677 | 0.87 | GGH (0.33) | FOLH1BLMGGH | |
| SCHEMBL27041682 | 0.87 | GGH (0.33) | FOLH1BLMGGH | |
| SCHEMBL14950991 | 0.86 | FOLH1 (0.32) | FOLH1NOS2NOS1NOS3CYP1A2 | |
| SCHEMBL15706851 | 0.86 | FOLH1 (0.32) | FOLH1NOS2NOS1NOS3CYP1A2 | |
| SCHEMBL24012407 | 0.83 | CNR2 (0.32) | FOLH1CNR2 | |
| SCHEMBL24012402 | 0.83 | CNR2 (0.32) | FOLH1CNR2 | |
| SCHEMBL14946315 | 0.81 | FOLH1 (0.41) | FOLH1TSHRALBNOD1 | |
| SCHEMBL13445978 | 0.81 | ALB (0.41) | FOLH1ALBNOD1 | |
| SCHEMBL24630046 | 0.79 | NOD1 (0.48) | FOLH1ALBNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-10745692-B2 | Production method for charged non-protein amino acid-containing peptide | THE UNIVERSITY OF TOKYO (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20160289668-A1 | Production Method for Charged Non-Protein Amino Acid-Containing Peptide | THE UNIVERSITY OF TOKYO (JP) | 2016-10-06 | — | — | US | disclosed |
| EP-3031915-A1 | PRODUCTION METHOD FOR CHARGED NON-PROTEIN AMINO ACID-CONTAINING PEPTIDE | The University of Tokyo (JP) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019999-A1 | PRODUCTION METHOD FOR CHARGED NON-PROTEIN AMINO ACID-CONTAINING PEPTIDE | 国立大学法人東京大学 (JP) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | FOLH1 19/4885NOS2 3352/4885NOS1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.